TRADING UPDATES: HSBC issues bond notes; Zegona to return capital
Mon, 24th May 2021 19:23
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:
Aberdeen Standard European Logistics Income PLC - European-focused logistics real estate investor - Posts net asset value peer share at March 31 of 121.6 euro cents, up from 120.1 cents at December 31. Declares first interim dividend of 1.41 cents per share. Portfolio valuation up 1.6% to EUR437.1 million from EUR430.2 million.
Accsys Technologies PLC - wood building products manufacturer - Says it has received valid acceptances under the open offer, announced early May, and the excess application facility significantly in excess of the 2.4 million new shares available. Says the gross proceeds of the open offer will be approximately EUR4 million, and the aggregate gross proceeds of the placing and the open offer will be around EUR37 million.
Researchers develop new way to evaluate tuberculosis treatments 18 May, 2021
Gregory Robertson, an assistant professor in the Department of Microbiology, Immunology and Pathology at CSU, is one of the first authors on the study. He said that the effectiveness of tuberculosis treatments has been judged by studying tissue cultures from infected patients. Photo: John Eisele/CSU Photography
Tuberculosis, a disease caused by the bacterium
Mycobacterium tuberculosis, is a serious global health threat. The disease caused an estimated 1.5 million deaths in 2019 and current methods often fail to predict treatment outcomes in patients.
Nature Communications provides an important new basis for comparing the effectiveness of different tuberculosis treatments and accelerating the development of shorter treatment regimens. The research team was led by scientists at the University of Colorado Anschutz Medical Campus with Colorado State University’s Mycobacteria Research Laboratories
COVID-19 is ravaging Brazil, and, in a disturbing new wrinkle that experts are working to understand, it appears to be killing babies and small children at an unusually high rate.
Similar Long-Term Outcomes With and Without ECMO for Mechanically Ventilated COVID-19 Patients
A nurse checking an ECMO system being used to support a critically ill COVID-19 patient at Banner Health in Phoenix. ECMO can offer both hemodynamic support and oxygenation for COVID patients who otherwise cannot get enough pulmonary support from ventilators, or are in danger of organ failure.
May 4, 2021 – A new study, presented today at the 2021 American Association for Thoracic Surgery (AATS) 101st annual meeting, found that severely ill COVID-19 (SARS-CoV-2) patients treated with extracorporeal membrane oxygenation (ECMO) did not suffer worse long-term outcomes than other mechanically-ventilated patients. The multidisciplinary team included cardio thoracic surgeons, critical care doctors, medical staff at long-term care facilities, physical therapists and other specialists, and followed patients at five academic centers: University of Colorado; University of Virginia; University of